The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
A meta-analysis on tens of thousands of individuals suggests cholesterol-lowering statin drugs may be particularly beneficial for those genetically prone to heart disease.
Cologuard will be available to Aetna's Medicare Advantage members through their physician without a co-payment or co-insurance.
Lilly decided to stop developing the drug in 2012, but Denovo thinks it can identify a subset of genetically defined patients that can benefit from the drug.
Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.
A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.
National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.
In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.